Revolution has set itself a mission to revolutionize treatment for patients with RAS addicted cancers. See why I upgrade RVMD ...

Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Revolution Medicines (RVMD – Research ...

Revolution Medicines (RVMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

The FDA last week announced that it is looking into the safety of bluebird bio ’s gene therapy Skysona (elivaldogene ...

Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies. A new approach aims to ...

LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist (GLP-1 RA) usage ...